Phase 3 Study of AMR101 for Hypertriglyceridemia - ONA

Links shared publicly online about this topic.

  • 356
    total visits

Phase 3 Study of AMR101 for Hypertriglyceridemia - ONA

oncologynurseadvisor.com

Amarin Corporation announced positive results from its Phase 3 study of AMR101 for the treatment of patients with high triglycerides (TG) without increasing LDL-C levels in patients on background statin therapy.

View full resource at oncologynurseadvisor.com

Tags: Phase 3 Clinical Trial

  • Share

Most Recently Shared on April 18, 2011 at 2:34 pm By:

ONAcom OncologyNurseAdvisor

Phase 3 Study of AMR101 for Hypertriglyceridemia http://goo.gl/fb/8o86e

1 year ago...

Phase 3 Study of AMR101 for Hypertriglyceridemia - MPR

empr.com — “Amarin Corporation announced positive results from its Phase 3 study of AMR101 for the treatment of patients with high triglycerides (TG) without increasing LDL-C levels in patients on background statin therapy.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 18, 2011 at 3:06 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 Study of AMR101 for Hypertriglyceridemia: Amarin Corporation announced positive results from i... http://bit.ly/dIGbsJ

1 year ago...

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C - Drugs.com MedNews

drugs.com — “- Triglyceride levels decreased 21.5 and 10.1 from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the pView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on April 18, 2011 at 2:15 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Signific... http://bit.ly/eofZrz #drug

1 year ago...

Phase 3 study of AMR101 for the treatment of hypertriglyceridemia - MPR

empr.com — “Amarin announced positive results from its Phase 3 study of AMR101 for the treatment of very high triglyceride levels or hypertriglyceridemia.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on November 30, 2010 at 10:44 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 study of AMR101 for the treatment of hypertriglyceridemia: Amarin announced positive results f... http://bit.ly/hrC6MV

1 year ago...

Phase 3 study of Epanova for the treatment of hypertriglyceridemia - MPR

empr.com — “Omthera has announced it has reached an agreement with the FDA on a Special Protocol Assessment (SPA) for the design of its planned Phase 3 registration clinical trial of Epanova (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) for the treatment of hypertriglyceridemia.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on November 23, 2010 at 7:17 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 study of Epanova for the treatment of hypertriglyceridemia: Omthera has announced it has reach... http://bit.ly/iiS4B9

1 year ago...

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

news-medical.net — “Essentialis, Inc. announced today that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 efficacy study required for product registration for its product candidate, Diazoxide Choline Controlled Release Tablet (DCCR), for the treatment of patients with very high triglycerides.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on October 25, 2010 at 11:37 am By:

NewsMedical News-Medical.Net Health News

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides: Essen... http://bit.ly/dCs6HA

2 years ago...

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

news-medical.net — “Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on January 12, 2010 at 8:57 am By:

Obesity_News News-Medical.Net Health News

Obesity News: Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease: Amar... http://twurl.nl/gx4uxx

2 years ago...

Phase 3 study of AMR101 for the treatment of high triglycerides - MPR

empr.com — “Amarin Corporation announced the enrollment of patients in their two Phase 3 trials of AMR101 for the treatment of patients with high triglycerides.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on January 11, 2010 at 5:01 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 study of AMR101 for the treatment of high triglycerides: Amarin Corporation announced the enroll... http://bit.ly/4Fss8g

2 years ago...

Advertisement